Skip to main content

Table 2 OS, PFS, and RR in patients with EGFR Mut + NSCLC

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

  n Overall survival Progression-free survival Response rate
  Median
(months)
95% CI Median
(months)
95% CI n %
Overall 320 17.2 15.1–19.8 9.1 8.5–10.3 163 50.9
Gender
 Female 200 20.4 17.2–23.8 10.3 9.4–12.6 110 55.0
 Male 120 12.2 9.6–17.0 6.8 5.1–8.8 53 44.2
   P < 0.001a   P < 0.001a    P = 0.078b
Histology
 Adenocarcinoma 286 17.0 15.1–19.5 9.3 8.7–10.5 148 51.7
 Non-adenocarcinoma 33 18.4 12.2–NA 6.9 5.1–21.3 15 45.5
     P = 0.82a    P = 0.616b
Smoking habit
 Ever smoker 168 15.1 13.6–18.1 8.1 6.8–10.3 79 47.0
 Never smoker 150 20.4 17.0–26.5 10.2 9.1–12.0 83 55.3
   P = 0.014a   P = 0.029a    P = 0.172b
First-line therapy
 Ever EGFR inhibitor 220 16.4 14.3–20.3 9.6 8.8–11.1 118 53.6
 No EGFR inhibitor 100 18.1 15.1–23.5 8.7 6.3–11.2 45 45.0
 Ever gefitinib 206 16.4 14.2–20.4 9.6 8.6–10.9 111 53.9
 TKI 188 17.4 14.7–20.4 9.7 8.5–11.4 100 53.2
 Gefitinib 176 17.4 14.7–20.4 9.6 8.1–11.3 94 53.4
 Chemotherapy 100 18.1 15.1–23.5 8.7c 6.3–11.2 45 45.0
 Chemotherapy → TKI 32 13.9 9.1–NA 9.2 8.6–21.6 18 56.3
 Chemotherapy → gefitinib 30 10.3 8.6–21.6 13.8 8.6–NA 17 56.7
 TKI maintenance planned 57 19.8 15.0–NA 10.3 8.7–16.3 38 66.7
 No TKI maintenance planned 263 16.4 14.2–19.1 9.0 7.7–10.3 125 47.5
 TKI from start 158 16.4 13.1–20.3 9.7 7.6–11.4   
 Change to TKI/planned TKI maintenance 76 17.9 14.8–NA 10.0 8.7–14.8   
 No TKI 86 18.0 14.2–22.5 8.1 6.1–11.2   
TKI treatmentd, e
 TKI from start 188 17.4 14.7–20.4 9.7 8.5–11.4   
 TKI switch/planned maintenance 46 17.0 10.0–NA 10.0 8.6–21.4   
 No TKI (first + maintenance) 86 18.0 14.2–22.5 8.1 6.1–11.2   
 TKI documented 229 17.9 15.0–20.5 10.1 8.9–11.7   
 Gefitinib documented 206 17.4 14.8–20.4 10.0 8.8–11.4   
 Planned TKI documented 12 NA NA 8.7 3.6–NA   
 No TKI documented 79 15.4 13.8–22.5 7.0 5.1–9.4   
TKI treatmente, f
 TKI documented 242 18.4 16.3–21.8     
 Gefitinib documented 213 18.1 15.5–21.4     
 Planned TKI documented 17 17.0 10.0–NA     
 No TKI documented 61 13.6 9.3–15.4     
EGFR mutation
 TKI-sensitive 231 18.1 15.5–20.9 10.2 9.1–11.7 132 57.1
 TKI-insensitive 24 17.9 6.9–NA 5.4 4.0–9.4 8 33.3
        P = 0.044b
  1. OS, PFS, and RR by demographic and clinico-pathological characteristics, and therapy in patients with EGFR Mut + NSCLC. aLog-rank test. bChi-squared test. cIncludes two patients in whom the therapeutic agent was changed within first-line treatment but the new agent was not documented. dTKI until first documented tumor progression. eAnalysis not prespecified. fPatients who ever received a TKI as part of their complete therapy course
  2. CI, confidence interval; NA, not available; NSCLC, non-small-cell lung cancer; RR, response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor